Global Cancer Genome Sequencing Market

Cancer Genome Sequencing Comprehensive Study by Type (Second Generation (SOLiD Sequencing, Pyro-Sequencing, Bridge Amplification Sequencing Technology), Third Generation (Ion Semiconductor Sequencing, Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, Fluorescent Resonant Energy Transfer (FRET) Sequencing)), Application (Treatment, Research) Players and Region - Global Market Outlook to 2028

Cancer Genome Sequencing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Cancer genome sequencing provides a base-by-base view of the unique mutations present in cancer tissue. It enables discovery of novel cancer-related variants, containing single nucleotide variants (SNVs), copy number changes, and structural variants. By comparing tumor and normal DNA, the cancer genome sequencing can also provide a comprehensive view of changes to a specific tumor sample. Many cancer-related variants have been discovered using cancer genome sequencing. As a hypothesis-free approach, cancer genome sequencing is well suited for the discovery of novel cancer driver mutations.This growth is primarily driven by Ability to Majority of Mutations .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Services sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Agilent Technologies (United States), GE Healthcare Life Sciences (United States), F. Hoffmann-La Roche Ltd (Switzerland), Johnson and Johnson (United States), LI-COR Biosciences (United States), GATC Biotech (Germany), Abbott Laboratories (United States), Eurofins Scientific (Luxembourg), Beckman Coulter (United States) and Bayer Corporation (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In April 2023, Agilent Announced NGS Assay for Comprehensive Genomic Profiling (CGP) for Advancing Precision On cology The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers.Cancer Genome Sequencing market companies operating in these industries are focusing more on efficient growth, improvement of operational efficiency and productivity, achieving high safety standards, and focusing on maintaining sustainable development. The market is highly competitive with a few players occupying the major share. The key players are highly focused on developing and innovating new strategies to maintain their market position and customer base. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launches, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Influencing Trend:
Technological Advancements in Cancer Genome Sequencing

Market Growth Drivers:
Ability to Majority of Mutations and Eliminating the Necessity of Having Any Knowledge Beforehand About the Patient History and Current Illness Status

Challenges:
Dearth of Skilled Professionals

Restraints:
Immense Procedural Expenses

Opportunities:
Lucrative Opportunities in Emerging Markets

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Cancer Genome Sequencing Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Cancer Genome Sequencing Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Cancer Genome Sequencing players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Cancer Genome Sequencing Study Sheds Light on
— The Cancer Genome Sequencing Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cancer Genome Sequencing industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cancer Genome Sequencing industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Second Generation [SOLiD Sequencing, Pyro-Sequencing, Bridge Amplification Sequencing Technology]
  • Third Generation [Ion Semiconductor Sequencing, Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, Fluorescent Resonant Energy Transfer (FRET) Sequencing]
By Application
  • Treatment
  • Research
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Ability to Majority of Mutations
      • 3.2.2. Eliminating the Necessity of Having Any Knowledge Beforehand About the Patient History and Current Illness Status
    • 3.3. Market Challenges
      • 3.3.1. Dearth of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Cancer Genome Sequencing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Genome Sequencing, by Type, Application and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Genome Sequencing (Value)
      • 5.2.1. Global Cancer Genome Sequencing by: Type (Value)
        • 5.2.1.1. Second Generation [SOLiD Sequencing, Pyro-Sequencing, Bridge Amplification Sequencing Technology]
        • 5.2.1.2. Third Generation [Ion Semiconductor Sequencing, Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, Fluorescent Resonant Energy Transfer (FRET) Sequencing]
      • 5.2.2. Global Cancer Genome Sequencing by: Application (Value)
        • 5.2.2.1. Treatment
        • 5.2.2.2. Research
      • 5.2.3. Global Cancer Genome Sequencing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Cancer Genome Sequencing (Price)
      • 5.3.1. Global Cancer Genome Sequencing by: Type (Price)
  • 6. Cancer Genome Sequencing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Agilent Technologies (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GE Healthcare Life Sciences (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson and Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. LI-COR Biosciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GATC Biotech (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott Laboratories (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eurofins Scientific (Luxembourg)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Beckman Coulter (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Genome Sequencing Sale, by Type, Application and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Genome Sequencing (Value)
      • 7.2.1. Global Cancer Genome Sequencing by: Type (Value)
        • 7.2.1.1. Second Generation [SOLiD Sequencing, Pyro-Sequencing, Bridge Amplification Sequencing Technology]
        • 7.2.1.2. Third Generation [Ion Semiconductor Sequencing, Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, Fluorescent Resonant Energy Transfer (FRET) Sequencing]
      • 7.2.2. Global Cancer Genome Sequencing by: Application (Value)
        • 7.2.2.1. Treatment
        • 7.2.2.2. Research
      • 7.2.3. Global Cancer Genome Sequencing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Cancer Genome Sequencing (Price)
      • 7.3.1. Global Cancer Genome Sequencing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Genome Sequencing: by Type(USD Million)
  • Table 2. Cancer Genome Sequencing Second Generation [SOLiD Sequencing, Pyro-Sequencing, Bridge Amplification Sequencing Technology] , by Region USD Million (2017-2022)
  • Table 3. Cancer Genome Sequencing Third Generation [Ion Semiconductor Sequencing, Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, Fluorescent Resonant Energy Transfer (FRET) Sequencing] , by Region USD Million (2017-2022)
  • Table 4. Cancer Genome Sequencing: by Application(USD Million)
  • Table 5. Cancer Genome Sequencing Treatment , by Region USD Million (2017-2022)
  • Table 6. Cancer Genome Sequencing Research , by Region USD Million (2017-2022)
  • Table 7. South America Cancer Genome Sequencing, by Country USD Million (2017-2022)
  • Table 8. South America Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 9. South America Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 10. Brazil Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 11. Brazil Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 12. Argentina Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 13. Argentina Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 14. Rest of South America Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 15. Rest of South America Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 16. Asia Pacific Cancer Genome Sequencing, by Country USD Million (2017-2022)
  • Table 17. Asia Pacific Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 18. Asia Pacific Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 19. China Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 20. China Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 21. Japan Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 22. Japan Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 23. India Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 24. India Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 25. South Korea Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 26. South Korea Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 27. Taiwan Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 28. Taiwan Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 29. Australia Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 30. Australia Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 31. Rest of Asia-Pacific Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 32. Rest of Asia-Pacific Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 33. Europe Cancer Genome Sequencing, by Country USD Million (2017-2022)
  • Table 34. Europe Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 35. Europe Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 36. Germany Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 37. Germany Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 38. France Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 39. France Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 40. Italy Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 41. Italy Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 42. United Kingdom Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 43. United Kingdom Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 44. Netherlands Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 45. Netherlands Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 46. Rest of Europe Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 47. Rest of Europe Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 48. MEA Cancer Genome Sequencing, by Country USD Million (2017-2022)
  • Table 49. MEA Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 50. MEA Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 51. Middle East Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 52. Middle East Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 53. Africa Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 54. Africa Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 55. North America Cancer Genome Sequencing, by Country USD Million (2017-2022)
  • Table 56. North America Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 57. North America Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 58. United States Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 59. United States Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 60. Canada Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 61. Canada Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 62. Mexico Cancer Genome Sequencing, by Type USD Million (2017-2022)
  • Table 63. Mexico Cancer Genome Sequencing, by Application USD Million (2017-2022)
  • Table 64. Cancer Genome Sequencing: by Type(USD/Units)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Cancer Genome Sequencing: by Type(USD Million)
  • Table 76. Cancer Genome Sequencing Second Generation [SOLiD Sequencing, Pyro-Sequencing, Bridge Amplification Sequencing Technology] , by Region USD Million (2023-2028)
  • Table 77. Cancer Genome Sequencing Third Generation [Ion Semiconductor Sequencing, Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, Fluorescent Resonant Energy Transfer (FRET) Sequencing] , by Region USD Million (2023-2028)
  • Table 78. Cancer Genome Sequencing: by Application(USD Million)
  • Table 79. Cancer Genome Sequencing Treatment , by Region USD Million (2023-2028)
  • Table 80. Cancer Genome Sequencing Research , by Region USD Million (2023-2028)
  • Table 81. South America Cancer Genome Sequencing, by Country USD Million (2023-2028)
  • Table 82. South America Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 83. South America Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 84. Brazil Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 85. Brazil Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 86. Argentina Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 87. Argentina Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 88. Rest of South America Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 89. Rest of South America Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 90. Asia Pacific Cancer Genome Sequencing, by Country USD Million (2023-2028)
  • Table 91. Asia Pacific Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 92. Asia Pacific Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 93. China Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 94. China Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 95. Japan Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 96. Japan Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 97. India Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 98. India Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 99. South Korea Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 100. South Korea Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 101. Taiwan Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 102. Taiwan Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 103. Australia Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 104. Australia Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 105. Rest of Asia-Pacific Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 106. Rest of Asia-Pacific Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 107. Europe Cancer Genome Sequencing, by Country USD Million (2023-2028)
  • Table 108. Europe Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 109. Europe Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 110. Germany Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 111. Germany Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 112. France Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 113. France Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 114. Italy Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 115. Italy Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 116. United Kingdom Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 117. United Kingdom Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 118. Netherlands Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 119. Netherlands Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 120. Rest of Europe Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 121. Rest of Europe Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 122. MEA Cancer Genome Sequencing, by Country USD Million (2023-2028)
  • Table 123. MEA Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 124. MEA Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 125. Middle East Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 126. Middle East Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 127. Africa Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 128. Africa Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 129. North America Cancer Genome Sequencing, by Country USD Million (2023-2028)
  • Table 130. North America Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 131. North America Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 132. United States Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 133. United States Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 134. Canada Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 135. Canada Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 136. Mexico Cancer Genome Sequencing, by Type USD Million (2023-2028)
  • Table 137. Mexico Cancer Genome Sequencing, by Application USD Million (2023-2028)
  • Table 138. Cancer Genome Sequencing: by Type(USD/Units)
  • Table 139. Research Programs/Design for This Report
  • Table 140. Key Data Information from Secondary Sources
  • Table 141. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Genome Sequencing: by Type USD Million (2017-2022)
  • Figure 5. Global Cancer Genome Sequencing: by Application USD Million (2017-2022)
  • Figure 6. South America Cancer Genome Sequencing Share (%), by Country
  • Figure 7. Asia Pacific Cancer Genome Sequencing Share (%), by Country
  • Figure 8. Europe Cancer Genome Sequencing Share (%), by Country
  • Figure 9. MEA Cancer Genome Sequencing Share (%), by Country
  • Figure 10. North America Cancer Genome Sequencing Share (%), by Country
  • Figure 11. Global Cancer Genome Sequencing: by Type USD/Units (2017-2022)
  • Figure 12. Global Cancer Genome Sequencing share by Players 2022 (%)
  • Figure 13. Global Cancer Genome Sequencing share by Players (Top 3) 2022(%)
  • Figure 14. Global Cancer Genome Sequencing share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 17. Agilent Technologies (United States) Revenue: by Geography 2022
  • Figure 18. GE Healthcare Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 19. GE Healthcare Life Sciences (United States) Revenue: by Geography 2022
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 22. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 23. Johnson and Johnson (United States) Revenue: by Geography 2022
  • Figure 24. LI-COR Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 25. LI-COR Biosciences (United States) Revenue: by Geography 2022
  • Figure 26. GATC Biotech (Germany) Revenue, Net Income and Gross profit
  • Figure 27. GATC Biotech (Germany) Revenue: by Geography 2022
  • Figure 28. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 29. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 30. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 31. Eurofins Scientific (Luxembourg) Revenue: by Geography 2022
  • Figure 32. Beckman Coulter (United States) Revenue, Net Income and Gross profit
  • Figure 33. Beckman Coulter (United States) Revenue: by Geography 2022
  • Figure 34. Bayer Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bayer Corporation (United States) Revenue: by Geography 2022
  • Figure 36. Global Cancer Genome Sequencing: by Type USD Million (2023-2028)
  • Figure 37. Global Cancer Genome Sequencing: by Application USD Million (2023-2028)
  • Figure 38. South America Cancer Genome Sequencing Share (%), by Country
  • Figure 39. Asia Pacific Cancer Genome Sequencing Share (%), by Country
  • Figure 40. Europe Cancer Genome Sequencing Share (%), by Country
  • Figure 41. MEA Cancer Genome Sequencing Share (%), by Country
  • Figure 42. North America Cancer Genome Sequencing Share (%), by Country
  • Figure 43. Global Cancer Genome Sequencing: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Agilent Technologies (United States)
  • GE Healthcare Life Sciences (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Johnson and Johnson (United States)
  • LI-COR Biosciences (United States)
  • GATC Biotech (Germany)
  • Abbott Laboratories (United States)
  • Eurofins Scientific (Luxembourg)
  • Beckman Coulter (United States)
  • Bayer Corporation (United States)
Additional players considered in the study are as follows:
Hamilton Thorne Biosciences (United States) , Microchip Biotech (United States) , Myriad Genetics (United States)
Select User Access Type

Key Highlights of Report


May 2023 223 Pages 74 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Genome Sequencing Market Quantitative research analysis
Global Cancer Genome Sequencing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Cancer Genome Sequencing Market are Agilent Technologies (United States), GE Healthcare Life Sciences (United States), F. Hoffmann-La Roche Ltd (Switzerland), Johnson and Johnson (United States), LI-COR Biosciences (United States), GATC Biotech (Germany), Abbott Laboratories (United States), Eurofins Scientific (Luxembourg), Beckman Coulter (United States) and Bayer Corporation (United States) etc.
Treatment segment in Global market to hold robust market share owing to "Ability to Majority of Mutations ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Cancer Genome Sequencing market throughout the forecasted period.

Know More About Global Cancer Genome Sequencing Market Report?

Have a Query? Click Here

Other Related Reports

Rehabilitation Swimming Pools Comprehensive Study by Type (Portable, Stationary), Treatment Type (Orthopedics, Obesity Crisis, Sports Rehabilitation, Others), End User (Human, Veterinary) Players and...
$ 3500
Patient Engagement Technology Comprehensive Study by Application (Health Management, Social and Behavioral, Home Health), Technology (Licensing fees, Implementation fees, Annual license maintenance f...
$ 3750
Lung Cancer Vaccines - Comprehensive Study by Type (Preventive Lung Cancer Vaccines, Therapeutic Lung Cancer Vaccines), Application (Hospitals, Clinics, Pharmacies, Vaccines Centers, Other, End user)...
$ 3450
Knee Replacement Surgery Comprehensive Study by Type (Total Knee Replacement, Partial Knee Replacement, Kneecap Replacement, Complex/Revision Knee Replacement), Application (Hospitals, Ambulatory Sur...
$ 3450
Kidney Stone Therapy Comprehensive Study by Type (Non-invasive Therapy, Minimally Invasive Treatment, Others), Application (Clinic , Hospital , Others), Stone type (Calcium Oxalate Stones, Uric Acid,...
$ 3750
Urethral Stricture Comprehensive Study by Type (Posterior Urethral Stricture, Anterior Urethral Stricture), Application (Hospitals, Gastrointestinal Surgery Clinics, Ambulatory Surgical Centers, Othe...
$ 3750